Evotec Management
Management criteria checks 2/4
Evotec's CEO is Christian Wojczewski, appointed in Jul 2024, has a tenure of 1.33 years. total yearly compensation is €1.07M, comprised of 42.1% salary and 57.9% bonuses, including company stock and options. directly owns 0.028% of the company’s shares, worth €260.29K. The average tenure of the management team and the board of directors is 1.4 years and 3.9 years respectively.
Key information
Christian Wojczewski
Chief executive officer
€1.1m
Total compensation
| CEO salary percentage | 42.06% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -€159m |
| Jun 30 2025 | n/a | n/a | -€156m |
| Mar 31 2025 | n/a | n/a | -€207m |
| Dec 31 2024 | €1m | €450k | -€196m |
Compensation vs Market: Christian's total compensation ($USD1.23M) is about average for companies of similar size in the Austrian market ($USD1.58M).
Compensation vs Earnings: Insufficient data to compare Christian's compensation with company performance.
CEO
Christian Wojczewski (52 yo)
Dr. Christian Wojczewski, Ph D., serves as Chief Executive Officer since July 01, 2024 & Member of Management Board at Evotec SE. He holds a diploma and a doctorate in chemistry from the Johann Wolfgang Go...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Management Board Member | 1.3yrs | €1.07m | 0.028% € 260.3k | |
| Chief Scientific Officer & Member of Management Board | 15.2yrs | €1.23m | 0.11% € 994.7k | |
| Chief People Officer & Member of Management Board | 1.4yrs | €469.00k | 0.0020% € 18.2k | |
| CFO & Member of Management Board | less than a year | no data | no data | |
| Executive VP and Head of Global Investor Relations & ESG | no data | no data | no data | |
| EVP Global Head of Legal & Compliance | no data | no data | no data | |
| Senior Vice President of Programme Management & Clinical Operations | no data | €116.00k | no data | |
| Executive Vice President | no data | no data | no data | |
| EVP Head of Metabolic Diseases | no data | no data | no data | |
| SVP Head of Diagnostics | no data | no data | no data | |
| Global Head & Executive VP of Partnering Excellence & Operations | no data | no data | no data | |
| Executive VP of Partnering & Transformation | no data | no data | no data |
Experienced Management: EVT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Supervisory Board | 1.4yrs | €44.71k | 0.0018% € 16.6k | |
| Independent Vice Chairperson of the Supervisory Board | 6.4yrs | €150.00k | no data | |
| Independent Chairperson of the Supervisory Board | 11.4yrs | €155.00k | 0.0084% € 78.1k | |
| Member of the Supervisory Board | 1.4yrs | €44.71k | no data | |
| Member of the Supervisory Board | 3.4yrs | €92.12k | no data | |
| Independent Member of Supervisory Board | 4.4yrs | €110.00k | no data |
Experienced Board: EVT's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 11:16 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evotec SE is covered by 25 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |